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Antiarrhythmic drugs, such as lidocaine, quinidine, and procainamide, have been shown to be effective against postischemic reperfusion injury in
isolated rat lungs. Rat lungs were perfused at a constant flow with Krebs-Henseilet buffer supplemented with 4% bovine serum albumin and venti-
lated with air containing 5% CO2. The lungs were subjected to ischemia by stopping perfusion and ventilation for 60 min followed by 30 min of
reperfusion. Lung injury was determined by measuring the increase in wet-to-dry lung weight ratio, while pulmonary arterial pressure and peak air-
way pressure were calculated from the pre- and postischemic differences. Lidocaine, quinidine, and procainamide at doses of 5, 10, and 20 mg/kg
body weight, respectively, were found to attenuate the postischemic lung injury significantly (p<0.0001). The formation of cyclooxygenase prod-
ucts, which were elevated during reperfusion, was also significantly (p<0.0001) inhibited by these drugs. Since these antiarrhythmic agents are
found to be powerful scavengers of hydroxyl radicals and can prevent membrane lipid peroxidation, these findings suggest that the antioxidant prop-
erties of these drugs may, in part, be responsible for protecting the lungs against reperfusion injury. - Environ Health Perspect 102(Suppl 10):
117-122 (1994)
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Introduction
Lung transplant is rapidly becoming a clin-
ical alternative for patients with end-stage
lung disease. Preservation of the cadaver
lung during transplant has been a major
impediment to the wide clinical use of
transplant procedures. Reperfusion of
transplanted lung previously subjected to
brief period of ischemia causes irreversible
tissue injury (1). Ischemia-reperfusion
injury has been extensively studied in many
organs, including brain, heart, intestine,
and kidney (2-7). Little work has been
done to elucidate the mechanism of reper-
fusion injury in the lung. Reactive oxygen
species has been implicated in the etiology
of ischemia-reperfusion injury (3,8-10).
Antiarrhythmic drugs have been used as
membrane stabilizers and were found to
prevent microvascular permeability result-
ing from acute lung injury (11). The
mechanism by which these antiarrhythmic
agents diminish lung edema, however, is
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unclear and their ability to reduce post-
ischemic reperfusion injury ofthe lung has
not been tested. Recently we reported that
antiarrhythmic agents such as lidocaine,
quinidine, and procainamide are potent
hydroxyl radical scavengers and were found
to inhibit lipid peroxidation (12). Since
free radicals ofoxygen are important in ini-
tiating lipid peroxidation (13,14), and
lipid peroxides are known to be produced
during postischemic reperfusion of lung
(15), we developed the hypothesis that
antiarrhythmic drugs may protect lungs
from reperfusion injury. Here we present
evidence that antiarrhythmic drugs such as
lidocaine, quinidine, and procainamide
attenuate postischemic reperfusion injury
in isolated perfused rat lung and these
drugs were effective in preventing the accu-
mulation of cyclooxygenase products dur-
ing reperfusion ofischemic lung.
Materials and Methods
Ea VivoLungPreparation
Male Sprague-Dawley rats (Harlan's
Sprague-Dawley, Dublin, VA) weighing
300 to 500 g were anesthetized with 64.8
mg/kg, ip, pentobarbital sodium (Anthony
Products Co., Arcadia, CA). A tra-
cheostomy was performed that permitted
ventilation with a Harvard rodent ventilator
(model 683) at 62 strokes per min, a tidal
volume of 2.3 to 3 ml, and positive end
expiratory pressure of 2.5 cm H20. The
inspired gas mixture was air mixed with 5%
CO2 (Analyzed, Industrial Gas and Supply
Co., Radford, VA). Subsequently a median
sternotomy was performed, heparin (200
IU) was injected into the rightventricle, and
cannulas were placed in the pulmonary
artery and left ventricle. The heart, lungs,
and mediastinal structures were removed en
bloc and suspended from a Fort-250 rigid
linear force transducer (World Precision
Instruments, New Haven, CT) to monitor
any weight change and placed in a
humidified chamber. The lungs were per-
fused by a masterflex pump (Cole Parmer
Instruments, Chicago, IL) with Krebs-
Hanseilet buffer at a constant flow of
0.05ml/min/g bw. The Krebs-Hanseilet
buffer contained 118 mM NaCl, 4.7 mM
KCl, 1.17mM MgSO4, 25 mM NaHCO3,
1.18 mM KH2PO4, 1.90 mM CaCl2, 11.1
mM glucose and 4% bovine serum albumin
(66,000 mw, Sigma Chemical Co., St.
Louis, MO). The pH of the perfusate was
maintained between 7.35 and 7.45 by peri-
odic addition ofsodium bicarbonate.
The first 50 ml of lung effluents were
discarded to eliminate circulating blood
elements from the vascular space of the
lung. Subsequently a recirculating mode
was established with 50 ml of perfusate.
Pulmonary artery pressure (Pa) was con-
stantly monitored with a transducer blood
pressure BPLR-0111 (WPI). Peak airway
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pressure (Paw) was constantly monitored
by a PNEU-01 (WPI) pressure transducer.
The pressure transducers were calibrated
with a blood pressure measurement instru-
ment (The Lumiscope Co.,[S-Nelkin
Home Care, APCC] Edison, NJ).
Mean pulmonary Pa, change in lung
weight, and mean peak Paw were con-
stantly monitored through the pressure and
linear force transducers connected to an
amplifier bridge (WPI). The bridge was
connected to a MacLab-4 (WPI) that in
turn was connected to a Macintosh SE
computer. The data were recorded by
Scope version 3.1 software for the MacLab
system (WPI).
InducionofLungIschemia
Isolated lungs were perfused for 10 min to
ensure a stable preparation and were then
subjected to ischemic injury for 60 min by
stopping ventilation and perfusion. The
lungs were inflated by instillating 2 ml of
gas mixture into tracheal cannula before
occlusion at the start ofthe ischemic period.
Lung inflation was done to facilitate reper-
fusion after ischemia. Throughout the 60-
min ischemia the lungs and perfusate were
kept at 37°C.
LungReperfision
Reperfusion after ischemic interval was
started slowly and the flow rate was
increased such that a mean pulmonary Pa
of 14 mm Hg was never exceeded. Within
5 min of the onset of the reperfusion the
perfusate flow was increased to the original
flow rate present before the ischemic period
(0.05 ml/min/g, bw). During reperfusion
the perfusate reservoir and the lungs were
maintained at 37 to 38°C. Lungs were
reperfused for 30 min while they were ven-
tilated with the same gas mixture.
Experimental Groups
Five experimental groups were studied. The
first group ofsix lungs underwent 60 min of
ischemia followed by 30 min ofreperfusion.
The same protocol was maintained for
groups 2, 3, and 4 (n=6) with the exception
that lidocaine, quinidine, and procainamide
at 5, 10, and 20 mg/kg bw, respectively,
were added to the perfusate. This dose was
calculated taking the blood volume at 8% of
the body weight. Group 5 served as control
and underwent no ischemia. The drugs were
added to the lung perfusate at the onset of
lung perfusion prior to ischemia.
MeasurementofLungInjury
Wet-to-Dry Lung Weight Ratio. At the
end ofeach experiment the left main stem
bronchus was transected and the left lung
was isolated for the determination of the
wet-to-dry lung weight ratio. Lungs were
weighed and placed in a convection oven
(Model 605, Precision Scientific Inc.,
Chicago, IL) at 1200C and weighed daily
for 3 days. Lung weight at 72 hr was
reported as dry weight because no further
weight loss occurred after that time.
Pulmonary Artery Pressure. Mean
pulmonary Pa was measured for 10 min
during the preischemic period and entire
postischemic period after the full flow was
resumed. Percentage change was calculated
taking the difference ofthe mean pre- and
postischemic pulmonary artery pressures.
Peak Airway Pressure. Mean peak
Paw was monitored for 10 min of pre-
ischemic period and 30 min during post-
ischemic period. Percentage change was
calculated taking the difference ofpre- and
postischemic pressures.
Measurement ofCydooxygenase
Metabolites
TxB2 and 6-keto-PGFia, the stable
metabolites of TxA2 and prostacyclin,
respectively, were measured as indicators of
cyclooxygenase metabolite production.
Samples (1.8 ml) of pulmonary venous
effluent were collected immediately before
the onset ofischemia, and at 5, 10, and 20
min ofreperfusion. Time-matched samples
were also obtained in the uninjured con-
trols. Measurements of TxB2 and 6-keto-
PGFIa were made in thromboxane B2
[3H] and 6-keto-PGF1J[3H] scintillation
proximity assay (SPA) systems [(16);
Amersham International Plc, Amersham,
UK] on methyl formate extracted samples
in duplicate (Bakerbond C18; J. T. Baker,
Inc., Phillipsburg, NJ).
StatisticalAnalysis
Values were expressed as mean± SEM.
Groups were compared using one-way
analysis ofvariance and the Tukey's multi-
ple comparison test using SAS statistical
software (SAS Institute, Cary, NC). Data
for PGFIa and TXB2 were analyzed by
two-way analysis of variance taking preis-
chemia and ischemia as factors. A p value
ofless than 0.05 was considered significant.
Results
EffectofAntiarrhythmicDrugs on
Wet-to-DryLungWeightRatio
Lung weight remained stable in uninjured
control lungs during the 100 min ofperfu-
sion. Lungs subjected to ischemia reperfu-
sion had increased lung weight at the end
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Figure 1. Effects of antiarrhythmic drugs on wet-to-dry
lung weight ratio of ischemic-reperfused rat lung. Wet-
to-dry lung weight ratios obtained after 100 min of
lung perfusion in experiments exposed to ischemia
reperfusion (I/R) and I/R with lidocaine, quinidine, and
procainamide at doses of 5, 10 and 20 mg/kg bw,
respectively (equivalent of 170, 320 and 900 pM,
respectively, in the perfusate). Values are mean ± SE.
*p<0.0001 compared with ischemia-reperfused lungs.
** p<0.0001 compared to the control. For each treat-
ment group, n=6.
of 30 min of reperfusion as recorded by a
MacLab-4 connected to a linear force
transducer (data not shown). Wet-to-dry
lung weight ratio, a measure ofedema for-
mation, was significantly higher
(p<0.0001) in ischemia-reperfused lungs
compared to uninjured controls (Figure 1).
The antiarrhythmic drugs lidocaine, quini-
dine, and procainamide at single doses of
5, 10, and 20 mg/kg bw, respectively,
significantly (p<0.0001) reduced the wet-
to-dry weight ratios compared to ischemia-
reperfused lungs (Figure 1).
Effect onPulmonaryPressure
Pulmonary Pa remained stable over the
100 min of perfusion in the control lungs
not subjected to ischemia. Lungs subjected
to 60 min of ischemia were allowed to
reach a stable Pa 10 min after the onset of
reperfusion. The Pa was found to be
significantly higher (p<0.008) 10 min after
the onset of reperfusion compared to the
pressures present in the same lung during
preischemia or compared to the Pa mea-
sured in the time-matched control lungs
(Figure 2). The Pa remained elevated com-
pared to preischemic values in the same
lung at 10 and 30 min after the onset of
reperfusion. Addition of lidocaine, quini-
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Figure 2. Effects of antiarrhythmic drugs on pulmonary
arterial pressure of ischemic-reperfused rat lung.
Uninjured control lungs were perfused for 100 min.
Lungs subjected to ischemia reperfusion underwent 10
min of preischemia followed by 60 min of ischemia and
30 min of reperfusion. Lidocaine, quinidine, and pro-
cainamide at doses of 5, 10 and 20 mg/kg bw, respec-
tively, were added to the perfusion buffer at the
beginning of perfusion. Results were expressed as per-
cent change in mean pulmonary arterial pressure
between preischemia and postischemic reperfusion.
*p<0.0001 and **p<0.008 compared to the control.
For each treatment group, n=6.
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Table 1. Effect of antiarrhythmic drugs on cyclooxygenase product formation in isolated rat lung si
ischemia reperfusion.
6-Keto-PGFia, pg/ml TxB2, pg/ml
Preischemiaa Postischemiab Preischemia Postisch
Controlc 220± 10 200± 20 58± 1.95 64±1
I/Rd 163 ± 15 1428 ± 315* 68± 1.28 132 ±9
I/R + lidocaine 205± 11 312± 63** 62± 1.68 85± 2
I/R + quinidine 250 ±36 209± 73** 55± 1.75 63± 1
I/R + procainamide 251 ± 15 282 ± 74** 55 ± 2.80 65 ± 1
aFirst 10 min of perfusion. bSamples taken 5 min after reperfusion. CControl lungs not subjected to is
perfused for 100 min. d60-min ischemia followed by 30 min of reperfusion. Lidocaine, quinidine and pr
at doses of 5, 10 and 20 mg/kg bw, respectively, were added to the perfusate at the begining of
*p<0001, compared to control; **p<0.001, compared to ischemia reperfusion.
no significant differences (Table 1). In the
ischemia-induced lungs, 5 min of reperfu-
sion resulted in 7- and 2-fold increases in
the production of the cyclooxygenase
metabolites, 6-keto-PGFia and TxB2,
respectively (Table 1). These increases were
ide significantly (p < 0.05) higher than either
control preischemic lung or preischemic
lung with addition of drugs in the per-
fusate (Table 1). The time course of accu-
mulation of these metabolites in lung
effluents was studied at 5, 10, and 20 min
postischemia. Both the 6-keto-PGFIa and
TxB2 levels were found to remain elevated
(p<0.0001) in the lung effluent collected
up to 20 min after reperfusion compared
to effluent collected from the same lung
prior to ischemia and when compared to
time-matched lung effluent samples from
control lungs not subjected to ischemia
In peak air- (Figures 4, 5). Effluents collected at 5, 10,
r 100 min. and 20 min after reperfusion from lungs
derwent 10 subjected to ischemia reperfusion and
chemia and treated with lidocaine, quinidine, and pro-
e, and pro- cainamide at 5, 10, and 20 mg/kg bw,
bw, respec- respectively, had significantly less
ffer at the (p<0.0001) 6-keto-PGFta and TxB2 com-
;sed as per- pared to untreated lungs that were sub-
e between jected to similar ischemia reperfusion
mp<0.aOdl conditions (Figures 4, 5). When the levels
mpared to of PGF1I and TxB2 were compared in
ent group, lungs subjected ischemia and reperfu-
sion, the levels of both cyclooxygenase
metabolites were found to be significantly
(p<0.05) higher 5 mmn after reperfusion,
when compared to effluents collected at 10
or 20 min after reperfusion. The levels of
emia PGFIa and TxB2 in effluents from of lungs
.47 treated with the antiarrythimic drugs were
1.68* also compared, with no significant change
..62** observed in levels of PGFia and TxB2
48** between quinidine and procainamide in effluents collected after 5, 10, or 20 min of
chemia but reperfusion. However, the lungs treated
ocainamide with lidocaine had significantly higher
perfusion. (p< 0.05) levels of PGFIa when compared
with control lungs or lungs treated with
quinidine or procainamide.
dine, and procainamide at 5, 10 and 20
mg/kg bw, respectively, significantly
reduced the Pa respectively, of ischemia-
reperfused lungs compared to untreated
reperfused lungs (Figure 2).
Effect on PeakAirwayPressure
Peak Paw remained stable over the 100
min of perfusion in the uninjured control
lungs. Lungs subjected to ischemia and
reperfusion had a significantly higher
(p< 0.0001) Paw after 30 min of reperfu-
sion. Lungs subjected to ischemia reperfu-
sion but treated with lidocaine (5 mg/kg
bw), quinidine (10 mg/kg bw), and pro-
cainamide (20 mg/kg bw) had significantly
(p<0.0001) reduced Paw compared to the
untreated ischemia-reperfused lungs. These
data are presented in Figure 3.
Effect ofAntiarrhythmic Drugs on
Cydooxygenase ProductFormation
Measurements of 6-keto-PGFia and TxB2
in lung effluents collected prior to ischemia
and in the time-matched lung effluents
from the uninjured control lungs showed
Discussion
A major source ofdamage in postischemic
reperfusion injury is believed to be the gen-
eration of oxygen-free radicals and other
toxic oxygen metabolites (9,17,18). These
radicals and metabolites have been impli-
cated in postischemic reperfusion injury in
the heart, kidney, intestine, brain, and
other organs (14,18-20). Studies in the
postischemic reperfusion injury of the
lungs also implicate toxic oxygen metabo-
lite as a source ofdamage (8,17,21,22). In
our present study, antiarrhythmic drugs,
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Figure 4. Effects of antiarrhythmic drugs on 6-keto-PGFia on ischemic-reper-
fused rat lung. Samples for 6-keto-PGFa, measurements were obtained prior
to ischemia as well as 5, 10, and 20 min after reperfusion or at time-matched
points in control lungs not subjected to ischemia. Lidocaine, quinidine, and
procainamide at 5, 10, and 20 mg/kg bw, respectively, were added to the per-
fusate at the beginning of the perfusion period. 6-keto-PGF1a was measured
by the scintillation proximity assay method on extracted samples in duplicate.
*p<0.0001 compared to control and drug-treated postischemic-reperfused
lungs. **p<0.05 when compared with control lungs or lungs treated with
quinidine or procainamide but significantly lowerthan the ischemia-reperfused
lungs. For each treatment group, n=6.
Figure 5. Effects of antiarrhythmic drugs on TxB2 on ischemic-reperfused rat lung.
Samples for TxB2 measurements were obtained prior to ischemia as well as 5, 10, and
20 min after reperfusion or at time-matched points in control lungs not subjected to
ischemia. Lidocaine, quinidine, and procainamide at 5, 10, and 20 mg/kg bw, respec-
tively, were added to the perfusate at the beginning of the perfusion period. TxB2 was
measured by the scintillation proximity assay method on extracted samples in dupli-
cate. *p<0.0001 compared to control and drug-treated ischemia-reperfused lungs. For
each treatment group, n=6.
such as lidocaine, quinidine, and pro-
cainamide, significantly reduced pul-
monary edema, pulmonary Pa and Paw.
These drugs also inhibited the formation of
cyclooxygenase metabolites known to be
produced during reperfusion of ischemic
lungs (23). Although these agents have
numerous systemic and local effects on var-
ious biological tissues, both in vivo and in
vitro (24,25), their ability to ameliorate
postischemic reperfusion injury in the
lungs has not previously been recognized.
The mechanism by which the antiar-
rhythmic agents are effective against reper-
fusion injury may be explained, in part, by
their antioxidant properties. In a recent
study, Stelzner et al. (11) found that these
drugs protect lungs against thiourea-
induced injury in rats. As oxygen radicals are
likely to be produced during metabolism of
thiourea (11), these authors speculated an
antioxidant action ofantiarrhythmic drugs.
However, they found that these drugs are
not scavengers of O°- or H202. Recently,
we have demonstrated that these drugs are
powerful hydroxyl radical scavengers
(k=1.8xloil, 1.61x10tl and 1.45x 101
M- sec-1 for quinidine, lidocaine and pro-
cainmide, respectively) and inhibitors of
lipid peroxidation (12). Therefore, it is
likely that these drugs protect pulmonary
tissue against postischemic reperfusion
injury by preventing lipid peroxide forma-
tion and/or scavenging -OH.
The concentration ofthree antiarrhyth-
mic drugs in the perfusat were 40, 120,
and 250 pg/ml for lidocaine, quinidine,
and procainamide, respectively. However
these drugs are also known to bind to
plasma albumin, thereby reducing the
availability of free drug for therapeutic
action (26). Since our perfusate contained
4% bovine serum albumin, the actual con-
centrations of free drugs may be much less
than indicated. The LD50 and pharmacoki-
netics ofthese drugs have not yet been elu-
cidated in rats. Taking into account the
doses of4, 20, and 30 mg/kg bw for lido-
caine, quinidine, and procainamide in the
study by Stelzner et al. (11), our doses of
40, 120, and 250 pg/ml for rats are
significantly smaller. Detailed pharmacoki-
netic studies of these drugs in rats are
needed to determine the typical nontoxic
plasma levels ofthese drugs in rats.
Because toxic oxygen metabolites can
directly cause cell injury or lead to the pro-
duction ofother mediators, such as arachi-
donate metabolites, we measured the effect
ofantiarrhythmic agents on the cyclooxyge-
nase metabolites thromboxane and prosta-
cyclin during the reperfusion of ischemic
lungs. Postischemic reperfusion caused a
significant elevation ofboth the thrombox-
ane and prostacyclin levels as measured by
their stable metabolites TxB2 and 6-keto-
PGFia. Similar increases of these metabo-
lites have been observed by Ljungman et al.
(16). It is believed that cyclooxygenase
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metabolites, produced secondary to the
production ofoxygen radicals, may in turn,
cause tissue damage (16). However, these
authors have concluded that cyclooxygenase
metabolites may not be the sole source of
injury because protection by inhibitors of
cyclooxygenase product formation was not
complete. Burghuber et al. (27) have also
reported similar findings and concluded
that cyclooxygenase products are not pri-
marily responsible for lung damage. It has
been shown that lidocaine is not an
inhibitor of prostaglandin biosynthesis in
vitro (28), but rather increases the produc-
tion ofprostacyclin (29). Our data demon-
strate that all these antiarrhythmic drugs
inhibit cyclooxygenase product formation.
Since -OH are known to be responsible for
the release of arachidonic acid from mem-
brane phospholipids (30), it is possible that
these drugs may not inhibit prostaglandin
formation per se but might inhibit the lib-
eration of arachidonic acid from phospho-
lipids by scavenging OH radicals.
Nevertheless, the lung damage imposed by
ischemia reperfusion could be the concom-
mitant actions of both toxic oxygen prod-
ucts (21) and cyclooxygenase metabolites
(23). We conclude that the inhibition of
cyclooxygenase product formation and the
attenuation of postischemic lung injury by
these drugs may, in part, be due to the
removal oftoxic oxygen metabolites gener-
ated during the reperfusion ofthe lung.
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